Clinical Trials Directory

Trials / Conditions / Stage IIIC Rectal Cancer AJCC v8

Stage IIIC Rectal Cancer AJCC v8

14 registered clinical trials studyying Stage IIIC Rectal Cancer AJCC v8 — 5 currently recruiting.

StatusTrialSponsorPhase
RecruitingActive Surveillance and Chemotherapy Before Surgery in Treating Participants With Stage II-III Rectal Cancer
NCT03594630
M.D. Anderson Cancer CenterEARLY_Phase 1
RecruitingAn Investigational Scan (64Cu-Labeled M5A Antibody) in Combination With SOC Chemotherapy and Radiotherapy in L
NCT05245786
City of Hope Medical CenterEARLY_Phase 1
RecruitingEstablishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer
NCT05081024
OHSU Knight Cancer Institute—
RecruitingShort Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer
NCT04703101
Jonsson Comprehensive Cancer CenterPhase 1
Active Not RecruitingLY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastat
NCT04616183
M.D. Anderson Cancer CenterPhase 1 / Phase 2
Active Not RecruitingSX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the S
NCT04599140
M.D. Anderson Cancer CenterPhase 1 / Phase 2
CompletedRegorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metast
NCT04362839
City of Hope Medical CenterPhase 1
Active Not RecruitingPanitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type C
NCT03992456
Academic and Community Cancer Research UnitedPhase 2
TerminatedGenetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Tr
NCT03765736
Academic and Community Cancer Research United—
Active Not RecruitingTAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer
NCT04104139
OHSU Knight Cancer InstitutePhase 1
TerminatedSavolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer
NCT03592641
National Cancer Institute (NCI)Phase 2
Active Not RecruitingFinancial Burden Assessment in Patients With Stage I-III Colon or Rectal Cancer Undergoing Treatment
NCT03516942
ECOG-ACRIN Cancer Research Group—
RecruitingEvaluation of Quality of Life and Utilities Following Surgical Treatment of Stage I-IV Rectal Cancer
NCT02107105
M.D. Anderson Cancer Center—
Active Not RecruitingCirculating Tumor Cells in Patients With Locally Advanced Rectal Cancer
NCT02874885
M.D. Anderson Cancer Center—